Abstract: This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula 1

Abstract: A new antioxidant neuroprotective use of and method of treatment using, selected hydroxycarbazole compounds or a pharmaceutically acceptable salt thereof. The new use of, and method of treatment using, the antioxidant compounds prevents oxidative tissue damage to organs, particularly the central nervous system including the brain in mammals afflicted with disease-induced ischemic trauma, particularly stroke.

Abstract: The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.

Abstract: Compounds characterized generally as alkylaminoalkyl-terminated &bgr;-alanineamide amino diol derivatives are useful as renin inhibitors for the treatment of hypertension.

Abstract: Pharmaceutical dosage forms for oral administration of an antihistamine and a decongestant are disclosed. The dosage forms provide an antihistamine in an amount and formulation to exhibit antihistaminic activity in a human for greater than 22 hours; and a decongestant in an amount and formulation to exhibit stimulatory activity in a human for less than 16 hours. The formulation of the invention can be taken once per day to afford symptomatic relief of rhinitis while avoiding stimulation at night.

Abstract: Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Abstract: Tannate compositions consisting essentially of carbetapentane tannate, phenylephrine tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis and upper respiratory tract conditions are disclosed.

Abstract: The present invention provides a dispersion of silica particle agglomerates having a sharp particle size distribution and capable of forming a porous coating film having a high transparency by drying.

Abstract: A silicone rubber composition comprising (A) an organopolysiloxane, (B) an inorganic filler, typically fumed silica, and (C) a specific halogen-free organic peroxide, typically 1,6-bis(p-toluoylperoxycarbonyloxy)hexane or 1,6-bis(benzoylperoxycarbonyloxy)hexane is safe and lends itself to atmospheric hot air vulcanization so that it can be extrusion vulcanized into silicone rubber having satisfactory physical properties without voids or surface tack. The silicone rubber composition is extrusion molded around an electrical wire, constructing a covered wire.

Abstract: Use as foaming agents having a low environmental impact of azeotropic or near azeotropic compositions using difluoromethoxy-bis(difluoromethyl ether) and/or 1-difluroromethoxy-1,1,2,2-tetrafluoroethyl difluoromethyl ether.

Abstract: The present invention involves the use of powder coating methods to form coated abrasives. In one embodiment, the powder is in the form of a multiplicity of binder precursor particles comprising a radiation curable component. In other embodiments, the powder comprises at least one metal salt of a fatty acid and optionally an organic component that may be a thermoplastic macromolecule, a radiation curable component, and/or a thermally curable macromolecule. In either embodiment, the powder exists as a solid under the desired dry coating conditions, but is easily melted at relatively low temperatures and then solidified also at reasonably low processing temperatures. The principles of the present invention can be applied to form make coats, size coats, and/or supersize coats, as desired.

Abstract: In the present invention, an inorganic reactant is, or reactants are, localized with respect to a dendritic polymer by physical constraint within or by a non-covalent conjugation to the dendritic polymer. The localized inorganic reactant or reactants is/are subsequently transformed to form a reaction product which is immobilized with respect to the dendritic polymer. This immobilization occurs on a nanoscopic scale as a consequence of the combined effects of structural, chemical and physical changes without having covalent bonds between the product(s) and the dendritic container and results in new compositions of matter called dendritic nanocomposites. The resulting nanocomposite material can be used to produce revolutionary products such as water soluble elemental metals, with specific applications including magnetic resonance imaging, catalytic, magnetic, optical, photolytic and electroactive applications.

Abstract: Iron oxide hydroxide composite particles having an average particle diameter of 0.005 to 1.

Abstract: A resin matrix with resistances to alkali and acid includes at least any one of insulative organic particles and insulative composite particles having an organic component and an inorganic component with the total amount of these particles being in the range of 5-50% by volume, wherein the insulative organic particles and the organic component of the insulative composite particles are allowed to be corroded by either alkali or acid, and wherein not less than 90% by volume of the insulative organic particles and insulative component particles have a particle diameter in the range of 1-20 micrometers.

Abstract: A wall repair compound useful for filling and repairing cracks, holes, and other imperfections in a wall surface includes a conventional filler material, a conventional binder material, and a dust reducing additive which reduces the quantity of airborne dust particles generated when sanding the hardened joint compound. Airborne dust reducing additives include oils, surfactants, solvents, waxes, and other petroleum derivatives. The additive can be added to conventional ready-mixed joint compounds and to setting type joint compounds. A method of reducing the quantity of airborne dust generated when sanding a fully hardened joint compound includes mixing a sufficient quantity of the dust reducing additive with the joint compound prior to when the joint compound has been applied to the wall.

Abstract: Asymmetrical bisbenzotriazoles of the formula I 1

Abstract: A polyolefin product can be coated with a matte, uniform coating having good adherence, good solvent resistance and good abrasion resistance. The coating includes a primary coating of a coating composition composed of a polymer solution or water dispersion of polyurethane or polyester in an amount of 100 parts by weight in solid content, and a polycarbodiimide compound in an amount of 2-100 parts by weight. A secondary coating is disposed on the primary coating. The secondary coating is formed from a solution of polyurethane with or without a carboxyl group.

Abstract: An activated, substantially water soluble poly(ethylene glycol) is provided having of a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups. The free reactive groups are capable of reacting with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated poly(ethylene glycol) and the biologically active agent.

Abstract: The present invention relates to a thermoplastic resin composition with excellent long-term heat-aging properties, comprising:

Abstract: Addition crosslinking silicone rubber mixtures comprising an alkenyl group—containing organopolysiloxane, a hydrogen siloxane, a Pt or Rh catalyst and an alkoxy silane or alkoxy siloxane.

Abstract: There is disclosed a thermoplastic resin composition comprising;

Abstract: Disclosed are (1) a thermopolymerizable composition containing a thermopolymerizable compound containing a (meth)acrylate having a moiety including oxyalkylene, fluorocarbon, oxyfluorocarbon and/or carbonate in the molecule, at least one electrolyte, and a polymerization initiator which is an organic peroxide containing no benzene ring, (2) a solid electrolyte obtained by thermally curing the composition, and (3) a primary battery, a secondary battery and electric double layer capacitor including the solid electrolyte, as well as a production method thereof.

Abstract: A process for the production of a cyclic siloxane described by formula

Abstract: The present invention provides a method of accelerating hardening of thermosetting resin and a device therefor such that hardening time is rendered far shorter than in the case of the prior art. By way of a pertinent means, when unhardened thermosetting resin is to be disposed in an atmosphere having a specified temperature for the purpose of hardening, a ceramic plasma spraying plane is formed in at least one portion, or preferably in as large an area as possible, in the above-mentioned atmosphere whose temperature is maintained at a specified level and in which the above-mentioned resin is disposed, thereby causing convective heat existing in the hot air to be thermally converted into far infrared radiant heat radiation from the ceramic plasma spraying plane mentioned above.

Abstract: The invention is an amidoamine epoxy curing agent composition, which comprises the reaction product of at least one aliphatic monobasic carboxylic acid, triethylenetetraamine, and an amine selected from the group consisting of polyethylenepolyamines higher than triethylenetetraamine, cycloaliphatic amines, and mixtures thereof, its method of use, and cured epoxy compositions made from it.

Abstract: The present invention provides: a process for treating a particulate water-absorbent resin, which enables to carry out pulverization stably in a process for producing a particulate water-absorbent resin, and transportation or storage of the particulate water-absorbent resin stably during or after producing the particulate water-absorbent resin, and to prevent contamination of cohered matters of the particulate water-absorbent resin; and involves no or little deterioration of properties. The process for treating a particulate water-absorbent resin is characterized by carrying out at least one selected from the group consisting of: (1) heating at least one portion of a surface getting contact with the particulate water-absorbent resin from the outside, (2) maintaining the temperature of at least one portion of a surface getting contact with the particulate water-absorbent resin at 30 to 150° C.

Abstract: hFrizzled-6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hFrizzled-6 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity, anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

Abstract: The invention provides a LM609 grafted antibody exhibiting selective binding affinity to &agr;v&bgr;3. The LM609 grafted antibody consists of at least one LM609 CDR grafted heavy chain polypeptide and at least one LM609 CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of &agr;v&bgr;3. The method consists of contacting &agr;v&bgr;3 with a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to &agr;v&bgr;3. Finally, the invention provides for a method of treating an &agr;v&bgr;3-mediated disease. The method consists of administering an effective amount of a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to &agr;v&bgr;3.

Abstract: The present invention has found that the Mts1 protein is expressed in white matter astrocytes in the spinal cord. Such expression is significantly increased following sciatic nerve injury or dorsal root injury, particularly in astrocytes surrounding dorsal funiculus containing the central processes of the injured primary sensory neurons. The present invention has further demonstrated that Mts1 proteins administered extracellularly promote neurite outgrowth from neuronal cells. Based on these surprising findings, the present invention provides compositions and methods that are useful for the treatment of various neurological conditions characterized by death, degeneration or injury of neuronal cells.

Abstract: The present application relates to a compositions comprising a compound which modulates the activity of T1-M protein, the use of compounds which modulate the activity of T1-M protein, and an in vitro method for influencing the proliferation and/or differentiation potential of bone cells.

Abstract: The present invention relates to a tumor-specific promoter for use in gene targeted therapy that is selectively activated in cancer cells, which comprises a Hex II promoter. The present invention also relates to a gene construct, which include a Hex II promoter in a vector selected from a basic expression vector, a shuttle plasmid, an adenovirus type 5 recombinant vector and a lipid-based delivery system.

Abstract: An analytical element (typically DNA chip) composed of a solid carrier and a group of nucleotide derivatives or their analogues fixed to the solid carrier via covalent bonding containing a boron-containing ring structure can be favorably prepared by bringing in a liquid phase a group of nucleotide derivatives or their analogues having at one end or its vicinity a boron-containing group or a divalent group reactive to the boron-containing group to produce a boron-containing ring structure into contact with a solid carrier having on its surface a divalent group reactive to the boron-containing group or a boron-containing group, respectively.

Abstract: The subject invention concerns the novel use of formyl-CoA transferase enzyme together with oxalyl-CoA decarboxylase enzyme for the detection and measurement of oxalate in biological samples. The use of the enzyme system according to the subject invention results in the conversion of oxalate into carbon dioxide and formate. Because the production of formate is directly correlated to the concentration of oxalate present in a sample, the determination of the resulting formate concentration provides an accurate, sensitive and rapid means for detecting even low levels of oxalate. The subject invention further concerns the cloning, sequencing and expression of the genes that encode the formyl-CoA transferase enzyme and the oxalyl-CoA decarboxylase enzyme of Oxalobacter formigenes.

Abstract: Nucleotide and amino acid sequences of cartilage-derived morphogenetic proteins (CDMP-1 and CDMP-2) from human and bovine cartilage extracts. These proteins exhibit chondrogenic activity and can be used to repair cartilage defects in a mammal.

Abstract: A process for producing cellullose acetate by acetylation reaction with cellulose as a raw material, wherein acetate is used as an acetylating agent.

Abstract: Disclosed are compounds of the formula: 1

Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: The present invention relates to the use of triphenylmethyl-1,2,3-triazoles for the production of a medicament for the control of disorders of the CNS, new active compounds, processes for their preparation, and their use, in particular as cerebrally active agents.

Abstract: According to a novel process, triazolinethione derivatives of the formula 1

Abstract: Dibenzorhodamine compounds having the structure 1

Abstract: The present invention relates to a method for preparing functional halosilanes by reacting

Abstract: A process for producing a pivaloylacetic acid ester comprises reacting pivaloyl chloride with an acetoacetic acid ester of an alkyl group having 1 to 4 carbon atoms in the presence of at least one nitrogen-containing basic compound (a) selected from among pyridine compounds, N,N-dialkylanilines and imidazole compounds and from 0.01 to 0.5 mole equivalent, based on the pivaloyl chloride, of a magnesium compound (b) to thereby prepare a pivaloylacetoacetic acid ester and then alcholyzing or alkali-hydrolyzing the pivaloylacetoacetic acid ester to thereby give a pivaloylacetic acid ester having a high purity at a low cost.

Abstract: The present application relates to a series of novel sulfonic acid metal cation salts of the formula 1

Abstract: A process for preparing phenoxyphenylsulfonyl halides, which are useful intermediates for the preparation of matrix metalloproteinase inhibitors.

Abstract: A tetrahydrofluorene, which is represented by the following formula (I) 1

Abstract: A process for the preparation of a compound having the formula

Abstract: The present invention relates to a compound having the formula: 1

Abstract: Method for obtaining components of a packet of additives for engine fuels by oxyalkylenation of organic compounds containing hydroxyl groups by means of alkylene oxide at the presence of basic catalysts, at the temperature 80-170° C., characteristic in that the mixture containing 94.5-99.9% by mass of alkyl phenols of the general formula according to FIG. 1, where R1-alkyl group of the carbon atoms number from 6 to 16 and not more than 0.1% by mass of water (H2O) and not more than 5.0% by mass (preferably from 0.1 to 1.0 by mass) of monohydroxyl alcohols of the general formula R2—OH, where R2-alkyl group of the carbon atoms number from 1 to 4, is oxyalkylenated with ethylene oxide or propylene oxide up to the moment of obtaining the molecular mass of oxyalkylenated alcohol not lower than 100 daltons and the hydroxyl number not higher than 150 mg of KOH/g, and next the product of synthesis is contacted at the temperature not higher than 150° C.